1286738-75-7

Upstream product

• 99-81-0 4-Nitrophenacyl bromide 
• 61192-65-2 2-(4-nitrophenyl)morpholine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6388-74-5 p-Nitrophenyloxirane 
• 21719-25-5 N-(2-hydroxy-2-(4-nitrophenyl)ethyl)-4-methylbenzenesulfonamide 
• 1393901-42-2 2-(4-nitrophenyl)-4-tosylmorpholine 
• 1286738-74-6 (2-hydroxyethyl)-[2-hydroxy-2-(4-nitrophenyl)ethyl]carbamic acid tert-butyl ester 

Downstream Products

• 1002726-96-6 2-(4-aminophenyl)morpholine-4-carboxylic acid tert-butyl ester 
• 1393901-43-3 tert-butyl 2-(4-((4-(2-(2-methoxy-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)morpholine-4-carboxylate 
• 1393901-44-4 2-(2-(2-(2-((4-(4-(tert-butoxycarbonyl)morpholin-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetic acid 
• 1393901-45-5 tert-butyl 2-(4-((4-(2-(2-amino-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)morpholine-4-carboxylate 
• 1393900-60-1 2-(2-(2-(2-((4-(morpholin-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1286738-81-5 C₂₅H₂₃BrClN₅O₂ 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

FAK AND FLT3 INHIBITORS

The use of a compound of the formula (I): (Formula (I)) in the preparation of a medicament for treating Acute Myeloid Leukemia or a disease ameliorated by the inhibition of Flt3, or Flt3 and FAK.

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

FAK INHIBITORS

A compound of the formula (I): where R1 or R2 is a cycle amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.